WCLC News

Drs. Mariam Jamal-Hanjani, Alan Sihoe, Anil Tibdewal, and Ross Soo discussed challenges and strategies across the lung cancer spectrum—from early-stage to oligometastatic and advanced disease.

Honorees Drs. Jessica Donington, Rafal Dziadziuszko, and Jie Wang presented thought-provoking talks on return to treatment after surgery, radiation oncology in Poland, and biomarkers in small cell lung cancer.

The IASLC Academy’s 2023 cohort spent months leading up to WCLC 2023 crafting case summaries in hopes of winning a spot in the association’s first case-based simulation course.

Drs. Silvia Novello, Alan Sihoe, and D. Ross Camidge kicked off the session with forward-looking talks on tobacco control and smoking cessation, surgery, and medical oncology.

After more than 2 years, the median duration of response was 12.4 months and no new safety signals were seen, according to Dr. Shirish Gadgeel, who presented the results during WCLC 2023.

Dr. Solange Peters presented new follow-up data from CheckMate 227 that show positive results regardless of PD-L1 expression.

During WCLC 2023, researcher Dr. Kevin Lamote shared data that demonstrated VOCs in exhaled breath could be a useful biomarker.

IASLC leaders also shared highlights from the association’s membership growth and financial report and officially welcomed President Dr. Paul Van Schil.

During the Presidential Plenary, investigator Dr. Eric Lim shared data comparing surgery plus chemotherapy to chemotherapy alone, one of several potentially practice-changing studies presented during the session.

Data presented by patient advocate Jill Feldman and Nathan Harrison show that while the IASLC’s Language Guide is helping to reduce the use of stigmatizing language, research on the effects of stigma in lung cancer is lacking.